Platinum-resistant ovarian cancer is the cancer nobody in the field wants to talk about.
After a patient’s disease stops responding to platinum chemo, options run out fast.
Avastin?
Elahere in folate receptor-positive disease.
PARP inhibitors in BRCA-mutated or HRD-positive disease.
After that, you’re looking at single-digit response rates on “let’s give it a shot” chemo regimens.
In this setting, Fast Track status points to real regulatory interest.
Debiopharm got one this week, for a combo of two of its own small molecules:
- lunresertib, a PKMYT1 inhibitor (formerly known as Debio 2513), and
- zedoresertib, a WEE1 inhibitor (Debio 0123).
The designation covers patients with CCNE1 amplification or FBXW7/PPP2R1A mutations. Phase 1 data were just presented as an oral at AACR 2026.
Debiopharm’s synthetic lethality stack
Lunresertib (Debio 2513)
PKMYT1 inhibitor
Blocks G2/M checkpoint entry in CCNE1-amplified cells.
Zedoresertib (Debio 0123)
WEE1 inhibitor
Forces mitosis through damaged DNA checkpoints.
Combination effect
Synthetic lethality in CCNE1-amplified / FBXW7 / PPP2R1A tumors
Two cell cycle choke points, hit at once.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you, contextualized and written directly to you, so you cut through the noise and immediately understand why it matters.
Both drugs converge on the same control point: the G2/M checkpoint.
Tumors with CCNE1 amplification or FBXW7/PPP2R1A mutations are already pushing through the cell cycle under replication stress. They rely heavily on WEE1 + PKMYT1 signaling to hold the line before mitosis.
Block both, and that checkpoint collapses.
Cells enter mitosis with damaged, incompletely replicated DNA, leading to catastrophic chromosome segregation and cell death.
A clean synthetic lethality play, but anchored to a defined genotype.
Debiopharm hasn’t published the specific response numbers from the AACR presentation, which is a little frustrating. Fast Track, though, is the FDA saying: we see enough here to want this to move faster.
Lunresertib originally came out of Repare Therapeutics‘ pipeline before being partnered with Debiopharm. Zedoresertib is Debiopharm-native. Combining the two is classic Debiopharm — a Swiss drug developer that likes to quietly stack mechanisms and run them in genetically-defined patient populations.
It’s also worth noting that Debiopharm just showed up in ViewsML’s seed round today, backing AI pathology tools. They’ve got a clear strategic lane: precision oncology, molecularly stratified patients, and the diagnostic infrastructure to find them.
Phase 2 is the number to watch.
If the ORR in CCNE1-amplified ovarian beats what chemo is doing now, which is a low bar but still a bar, Debiopharm has a real ovarian drug on its hands.
